Toll样受体4是预防和治疗肝衰竭的治疗靶点
本研究评估抑制TLR4信号能否改善肝衰竭。在肝硬化患者中,肝脏TLR4表达上调且循环TLR4配体增加(p<0.001)。在 rodents 的ACLF和ALF模型中,TAK-242(TLR4抑制剂)改善无昏迷生存、减少肝细胞死亡和循环细胞因子,并预防器官损伤和全身炎症。结论:TLR4信号是ACLF和ALF发展的关键因素,抑制其可减轻器官损伤严重程度并改善结局。
要点
- 肝硬化患者肝脏TLR4表达上调和循环TLR4配体增加。
- TAK-242在ACLF和ALF动物模型中减少器官损伤和炎症。
- TLR4抑制可能成为肝衰竭的潜在治疗策略。
核心结论
- TLR4信号是ACLF和ALF发展的关键因素,抑制其可减轻器官损伤严重程度并改善结局。
研究设计与样本
- 测量肝硬化患者血浆和肝活检中的循环TLR4配体和肝脏TLR4表达。
- 在ACLF(胆管结扎+脂多糖;四氯化碳+脂多糖)和ALF(半乳糖胺+脂多糖)啮齿动物模型中测试TAK-242(10 mg/kg腹腔注射)。
- 体外实验使用永生化人单核细胞(THP-1)和肝细胞(HHL5)。
主要发现
- 肝硬化患者肝脏TLR4表达上调且循环TLR4配体增加(p<0.001)。
- 啮齿动物ACLF与ALF中细胞死亡从凋亡向非凋亡形式转换相关。
- TAK-242在体外减少LPS诱导的细胞因子分泌和细胞死亡(p=0.002)。
- 在ACLF啮齿动物模型中,TAK-242改善无昏迷生存、减少肝脏(p<0.001)和肾脏(p=0.048)肝细胞死亡程度并降低循环细胞因子水平(IL-1β,p<0.001)。
- 在ALF啮齿动物模型中,TAK-242预防器官损伤(p<0.001)和全身炎症(IL-1β,p<0.001)。
临床怎么用
- TAK-242可能对肝衰竭患者具有治疗相关性,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Toll-like receptor 4 (TLR4) plays an essential role in mediating organ injury in acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Herein, we assess whether inhibiting TLR4 signaling can ameliorate liver failure and serve as a potential treatment. METHODS: Circulating TLR4 ligands and hepatic TLR4 expression were measured in plasma samples and liver biopsies from patients with cirrhosis. TAK-242 (TLR4 inhibitor) was tested in vivo (10 mg/kg intraperitoneally) in rodent models of ACLF (bile duct ligation + lipopolysaccharide [LPS]; carbon tetrachloride + LPS) and ALF (galactosamine + LPS) and in vitro on immortalized human monocytes (THP-1) and hepatocytes (HHL5). The in vivo therapeutic effect was assessed by coma-free survival, organ injury and cytokine release and in vitro by measuring IL-6, IL-1β or cell injury (TUNEL), respectively. RESULTS: In patients with cirrhosis, hepatic TLR4 expression was upregulated and circulating TLR4 ligands were increased (p <0.001). ACLF in rodents was associated with a switch from apoptotic cell death in ALF to non-apoptotic forms of cell death. TAK-242 reduced LPS-induced cytokine secretion and cell death (p = 0.002) in hepatocytes and monocytes in vitro. In rodent models of ACLF, TAK-242 administration improved coma-free survival, reduced the degree of hepatocyte cell death in the liver (p <0.001) and kidneys (p = 0.048) and reduced circulating cytokine levels (IL-1β, p <0.001). In a rodent model of ALF, TAK-242 prevented organ injury (p <0.001) and systemic inflammation (IL-1β, p <0.001). CONCLUSION: This study shows that TLR4 signaling is a key factor in the development of both ACLF and ALF; its inhibition reduces the severity of organ injury and improves outcome. TAK-242 may be of therapeutic relevance in patients with liver failure. LAY SUMMARY: Toll-like receptor 4 (or TLR4) mediates endotoxin-induced tissue injury in liver failure and cirrhosis. This receptor sensitizes cells to endotoxins, which are produced by gram-negative bacteria. Thus, inhibiting TLR4 signaling with an inhibitor (TAK-242) ameliorates organ injury and systemic inflammation in rodent models of acute and acute-on-chronic liver failure.
引用
- Engelmann C, Sheikh M, Sharma S, et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. J Hepatol. 2020. PMID: 31987990. doi:10.1016/j.jhep.2020.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。